Research ArticleSpondyloarthritis
A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis
Peter C. Taylor, Désirée van der Heijde, Robert Landewé, Shannon McCue, Sue Cheng and Annelies Boonen
The Journal of Rheumatology August 2021, 48 (8) 1259-1267; DOI: https://doi.org/10.3899/jrheum.201088
Peter C. Taylor
1P.C. Taylor, PhD, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK;
Désirée van der Heijde
2D. van der Heijde, MD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands;
Robert Landewé
3R. Landewé, MD, Amsterdam University Medical Center, Amsterdam, and Zuyderland Medical Center, Heerlen, the Netherlands;
Shannon McCue
4S. McCue, PhD, S. Cheng, MD, Amgen Inc., Thousand Oaks, California, USA;
Sue Cheng
4S. McCue, PhD, S. Cheng, MD, Amgen Inc., Thousand Oaks, California, USA;
Annelies Boonen
5A. Boonen, PhD, Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Center, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands.
In this issue
The Journal of Rheumatology
Vol. 48, Issue 8
1 Aug 2021
A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis
Peter C. Taylor, Désirée van der Heijde, Robert Landewé, Shannon McCue, Sue Cheng, Annelies Boonen
The Journal of Rheumatology Aug 2021, 48 (8) 1259-1267; DOI: 10.3899/jrheum.201088